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Abstract
and
Broderick, Patricia A., Omotola Hope and Pierrot Jeannot: Mechanism of Triazolo-Benzodiazepine
Benzodiazepine Action in Anxiety and Depression: Behavioral Studies with Concomitant In Vivo CA,
Hippocampal Norepinephrine
and Serotonin Release Detection in the Behaving Animal. Prog. Neuro0 1998 Elswier sdence IX-C.
Psychopharmacol.
t Biol. Psychiat. 1998, 22. PP. 353-386.
1.

2.

3.

4.

5.

6.

Real time, in vivo microvoltammetric

studies were performed, using miniature carbon-based
sensors, to concurrently detect norepinephrine
(NE) release and serotonin (5-HT) release, in 2
separate electrochemical
signals, within CA, region of hippocampus in the freely moving and
behaving, male, Sprague Dawley laboratory rat.
Concurrently, four parameters of open-field behavior, i.e. Ambulations, Rearing, Fine Movements
and Central Ambulatory behavior (a measure of anxiety reduction behavior), were assayed by
infrared photobeam detection.
Time course studies showed that the mechanism of action of the triazolobenzodiazepine
(TBZD),
adinazolam, (Deracyn@) is dramatically different from that of the classical benzodiazepine (BZD),
diazepam (Valium@), i.e., adinazolam increased, whereas diazepam decreased, 5-HT release within
CA, region of hippocampus in the freely moving and behaving rat.
Adinazolam initially increased NE release and then decreased NE release in CA, region of
hippocampus
in the freely moving and behaving rat whereas diazepam only decreased the
electrochemical
signal for NE; the decrease in NE produced by adinazolam was greater than the
decrease in NE release produced by diazepam.
The Behavioral Activity Patterns, derived from same animal controls, simultaneously
with
detection of in vivo microvoltammetric
signals for NE release and 5-HT release, showed that the
BZD, diazepam, exhibited more potent sedative properties than did the TBZD adinazolam.
Hippocampal 5-HT and NE release effects of the TBZD, adinazolam, concomitant with behavioral
effects lends explanation to the dual anxiolyticlantidepressant
properties of the TBZDs.

4 Presently at Univ. of Penn. School of Med., PA; MD Program, 5 Presently at SUNY Health Sci. Ctr. at
Brooklyn, NY; MD Program..
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Keywoh:
adinazolam (DeracynQ, carbon paste microelectrode, diazepam (Valium@), freely moving
animal, hippocampus, infrared photocell beams, in vivo microvoltammetry,
norepinephrine, open-field
behavior, serotonin, stearate.
Abbreviatiou:
benzodiazepine (BZD), dorsal raphe (DR), gamma-aminobutyric
acid (GABA), gammabutyrolactone
(GBL), intraperitoneal
(i.p.), locus coeruleus (LC), norepinephrine
(NE), platelet
activating factor (PAF), serotonin (%HT), triazolobenzodiazepine
(TBZD), tricyclic antidepressant
(TCA).

lntroductian
The benzodiazepines

(BZDs) comprise treatment for the generalized

triazolobenzodiazepine

(TBZD) and a dual anxiolytic/antidepressant

1994; Petty et al., 1995) is included in this listing (Baldessarini,
anxiety disorders

pharmacotherapy

1996). In addition,

oxidase inhibitors

(1988) showed
effectively
specific
receptors.

that the chronic

alleviated anxiety,

Furthermore,

administration

and was not mediated

after acute administration,

therapy,
feeding”,

Bodnoff

i.e., a BZD,

and desmethylimipramine,

expectedly

acid (GABA)

alleviated anxiety

triazolobenzodiazepine

(Valium@),

between anti-anxiety

and those

(TBZD) such as adinazolam. (Deracynm).

Therefore,

appears to be superimposed

that an overlap between neural transmitter mechanisms

like diazepam

et al.,

were tested, i.e. the BZD, diazepam,

these compounds

A pivotal focus to the present studies, is the distinction

These

are supported by

through gamma-aminobutyric

of action for “anxiety” and for “depression”,

is reasonable to hypothesize

“typical”

(TCAs) and to the

acted via GABA and in a manner which was not specific to novelty.

behavioral mechanism

to the

effect, produced by TCAs, was shown to be

in the same study, two BZD compounds

and the TBZD, adinazolam;

suppressed

of TCAs, amitryptiline

albeit that this anti-anxiety

to a novel environment

and expectedly

types of

(Sheehan et al., 1980; Pohl et al., 1982; Charney et al., 1986).

data. Using an animal model of anxiety, “novelty

a

(Zarcone et al.,

differential

(Fleishaker et al., 1994) as well as to the tricyclic antidepressants

clinical data which indicate that anxiety can be alleviated by “antidepressant”
preclinical

Alprazolam,

such as panic disorder and phobia, have shown a favorable clinical response

TBZD adinazolam
monoamine

anxiety disorders.

which

the

and it

may exist as well.

agents which are called

are called

“atypical”,

i.e., a

One distinction between the typical

and atypical BZD’s is seen in chemical structure; diazepam has a methoxy group in place of the triazolo
group.

Furthermore,

the TBZDs, such as alprazolam

(Xanax@) and triazolam

(Halcionm),

not only

differ in structure from the BZDs but also differ in metabolic pathways (Gall et al., 1978). Yet, TBZDs
are very potent members

of the BZD class and the TBZDs share with the BZDs, the same favorable

therapeutic ratio. The actual discovery of the dual anxiolytic and antidepressant

activity of the TBZDs

Adinazolam.

diazepam,

was made during the broad pharmacological

5-HT,

NE,

open field behavior

and clinical screening of the TBZD series of compounds

(Hester et al., 1971; Hester et al., 1980; Pyke et al., 1983; Hoehn-Saric,
compound

to adinazolam,

has been commonly
insomnia (Sheehan,

alprazolam,

used in the clinical management

clinical

results

with depressive

activity clinically
derived

mechanistically

of mild depressive

syndromes

group,

with anxiety and

from

the

a strategic step in the therapy of patients who present

affect.

Diazepam, the typical BZD, on the other hand, has

(Lafaille et al., 1991).
TBZDs

from a preclinical viewpoint.

on depression,

The situation remains though, that the
have

virtually

never

been

explained

For example, although the NE and 5-HT monoamines

integral to cutient thinking about the neurochemistry
adinazolam

Indeed, the sister

1980; Chouinard et al., 1982; Shader et al., 1982; Fawcett et al., 1987).

with anxiety concomitantly
antidepressant

1982).

differing from adinazolam only by a terminal aminoethyl

Clearly, the discovery of the TBZDs represents

no

355

of depression

are

(Sulser, 1983; Asnis et al., 1992),

has been reported to have only weak inhibitory effects on NE reuptake (Sethy and Harris,

1981), no specific effect on inhibiting the reuptake of 5-HT (Lahti et al., 1983) and no effect on dorsal
raphe (DR) 5-HT neuronal firing (Tunnel and de Montigny,
previous

in situ, in vitro and anesthetized

studies used, had inherent limitations

which masked the detection of changes in the monoamines
microvoltammetry

with a miniaturized

the effects of adinazolam
surrounding

spatial resolution
neurochemical

on CA, hippocampal

of open-field

behavior.

of both behavioral

system was utilized to study

Our hypothesis

beams.

digital and analog record of each

was that the uniquely high temporal
technologies

would aid in revealing

and
the

for the on-line NE signal came from the following studies which showed that (a) the NE
of the a, adrenergic antagonist, yohimbine,

of the a2 adrenoceptor

that the NE peak can be detected

agonist, clonidine (Broderick,

electrochemically

et al., 1990; Sauad-Chagny

et al., 1990).

199la; Broderick,

by an oxidation
Validation

and decreased

reaction

after

1997) and (b)

of this monoamine

for the 5-HT peak came from the

(a) studies which showed that the 5-HT peak increased after the administration

precursor, I-tryptophan
decreased

potentiostat

and behavioral effects of adinazolam.

the administration

following:

Therefore, in vivo

NE and S-HT release while infrared photocell

and neurochemical

peak increased after the administration

(Mermet

three-microelectrode

was that the

in the technologies,

produced by adinazolam.

the faradaic shielded chamber, performed a computerized

separate component

Validation

1984). The present hypothesis

of the 5-HT

(Broderick and Jacoby, 1988), and (b) studies which showed that the 5-HT peak

after the administration

of the 5-HT,,

1989; Broderick and Piercey, 1990).

agonists, buspirone

and ipsapirone

(Broderick

et al.
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Multiple neurotransmitters

are detected

with in vivo microvoltammetry.
integral relationship

in one voltammogram

in a matter of seconds

In the present paper, NE and S-HT are the focus because

with anxiety and depression.

in the CA, area of hippocampus,
on data, mentioned

or recording

Detection of synaptic concentrations

are release mechanisms,

above, that adinazolam

primarily.

This conclusion

in vitro, but also on data which showed that gamma-butyrolactone

depolarization

blocker (Walters and Roth, 1972), decreased 5-HT concentrations
animal (Broderick,

The hippocampal

formation

is organized

hippocampal

into subcortical

site for these studies,
formation

is divided

subdivisions;

radiatum,

the pyramidale,

Pyramidal

neurons

extrinsic connections

of Cornu Ammonis.

is one subdivision

within the subcortical

into hippocampus

pyramids

proper, also known as Cornu
CA, , CA, , CA,, and CA,

are lamellar and the moleculure,
a pyramid

of the CA, region, the regio superior, are medium

innervate the nucleus accumbens

the

( Ramon y Cajal, 1955).

sized and have intrinsic

which innervate the subiculum and provide the origin of the hippocampal

studies

of the CA, region have demonstrated

densely innervated with 5-HT projections
a 5-HT innervation

1977); LC is a primary

and

outflow

of the ventral striatum, brain reward

source of

noradrenergic

innervation

is

DR (Jacobs and Azmitia, 1992).

to the locus coeruleus (LC) has been demonstrated

HT, and 5-HT, class (Andrade and Chaput, 1991). Importantly,
used in these studies,

that this region of hippocampus

from 5-HT somatodendrites,

pyramidal neurons of the CA, region exhibit a pharmacological

as well (Pickel et al.

to the hippocampus.

Hippocampal

profile similar to that of the 5-HTlp,

5-

the miniature sensors (microelectrodes

have a sensitive spatial resolution, amenable for detection of NE and 5-HT within

the CA, region of Cornu Ammonis. (Broderick,
Anxiety and depression
expressed

region.

through the fomix (Amaral and Insausti, 1990).

Neurochemical

Moreover,

CA,

the oriens and the alveus comprise

in the fomix; longer projections
circuits,

in the chloral hydrate

CA, region of hippocampus,

Ammonis (hence, CA or CA pyramid), the dentate gyrus and the subiculum;
are further subdivisions

(GBL), a neuronal

199 1b; Broderick, 1992).

selected as the neuroanatomical
The subcortical

of NE and 5-HT
is based not only

has only weak effects on NE reuptake and no effects on 5-

HT reuptake

anesthetized

of their

are personified

1997).

within the act of behaving.

in a variety of ways which are behaviorally

dependent

Anxiety and depression
on the environment

can be

and specific

behavioral tests and responses to novelty have played a substantial role in animal models of affective

Adinazolam.
disorders.

Although

open-field

1971), simply monitoring

diazepam,

behaviors

behaviors was undertaken
i.e., Ambulations,

Oades considers

neurons to simultaneously
Inhibition

“shift” mechanism

(Gray,

paradigm becomes a complex
a separation of open-field

in these studies, to decipher four separate parameters of open-field

behaviors,

and Central Ambulatory behavior.

NE and 5-HT have been implicated

Interestingly,

Behavioral

in an open-field

behavior (Gray, 1982). Therefore,

Rearing, Fine Movements

Both hippocampal
paradigm.

have been reliable assays in these animal models

a parameter like Ambulations

measure of both anxiety and exploratory

357
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hippocampal

in the process of behaving

NE as a neuromodulator

in an open-field

that can inhibit CA,

censor and select specific sensory stimuli (Oades, 1985). Moreover,

Theory, hippocampal

5-HT has been considered

significant

as relevant

changing from ongoing behavior to new behavior in a novel environment

in the
to the

(Soubrie.

1986).
Therefore,
(diazepam)

the purpose

of the present

paper was to compare

TBZDs

(adinazolam)

with BZDs

in an in vivo paradigm with which we were able to use same animal control to examine

electrochemical

signals for NE and separate electrochemical

release, during time course studies.
CA, hippocampal

signals for 5-HT, each within seconds of

The purpose was to detect changes in synaptic concentrations

NE and 5-HT during the time in which open-field behavioral changes were actually

occurring, in order to decipher a possible preclinical mechanism
dual antianxiety-

of

antidepressant

of action for the clinically documented

activity of adinazolam.

Methods

The studies were done with unrestrained,

freely moving, male, Sprague Dawley rats (Charles River.

Kingston, NY) (weight range 312 to 417 grams at the time of the in vivo electrochemical

and behavioral

(adinazolam)

and behavioral

(diazepam)

studies;

300 to 440 grams at the time of the in vivo electrochemical

studies). The animals were fed Purina Rat Chow and water ad lib. and were group housed

before surgery and individually

housed after surgery.

A twelve hour dark/light cycle was maintained

both during the housing of the laboratory rats and throughout
were tested free from the following
Sialodacryoadenitis
Lymphocytic

Virus,

viruses:

Sendai Virus, Kilham

Rat Corona Virus, Toolan’s

Choriomeningitis

the experimental

studies.

The animals

Rat Virus, Reo Virus Type 3,

Hl Virus, Micro Plasma

Virus, Hantaan Virus and Enchephalitozoon

Pulmonis

Virus.

Cuniculi Virus. Virus free

animals allow a safer surgical procedure and a more efficacious and faster recovery from surgery.

P.A. Broderick et al.
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The general

anesthetic,

surgical anesthesia.

pentobarbital

A supplemental

Na (50 mg/kg intraperitoneally

dose of pentobarbital

(i.p.)) was used to produce

Na (0.10 cc of the same 6% solution) was

administered

once after the first two hours of surgery and another supplemental

administered

in each of the two subsequent

dose (0.05 cc) was

hours of surgery in order to maintain adequate anesthesia.

Animals were tested for comeal, pinnal, and leg flexion responses; the absence of these reflexes denoted
adequate

anesthetic

thermometer

induction.

Body

temperature

was

(Fisher Sci., Fadem, NJ) and was maintained

continuously

monitored

Tujunga,

microelectrodes
assembly

CA).

implanted

(made in this laboratory) within CA, region of hippocampus

2.6,‘ML= +2.25, DV=-2.7) (Pellegrino
Stereotaxic,

a rectal

at 37’C +/- OS’C with an aquamatic

module heating pad (Amer. Hosp. Supply, Edison, NJ). Animals were stereotaxically
Broderick Probe@ microelectrodes

with

et al., 1979). (Stereotaxic

Ag/AgCl

reference

K

with
(AP=-

equipment was purchased from Kopf

microelectrodes

and

(made in this laboratory) were placed in contact with cortex.

stainless

steel

auxiliary

The three microelectrode

was held in place with dental acrylic (Kadon Cavity Liner, Caulk, Becker-Parkin

Dental

Supply Co. Inc., NY). Animals recovered in a bedded Plexiglas chamber (dimensions

12” x 12”~ 18”).

Animals were treated with physiological

after surgery.

In Vivo Electra-

this laboratory (Broderick,
electrochemistry

of each neurotransmitter

of molecules

current.

1989; Broderick,

regression

hippocampus.

of time in seconds.
according

Current was directly

to the Cottrell Equation,

6 nmoles and 3 mnoles, respectively

1993; Broderick,

1997).

which

peak which denotes

analysis indicated that the lowest detection

limits for

in the first preconcentration

The current produced

by the oxidation

step
of NE

was detected in lo- 15 seconds whereas that produced by 5-HT was

detected in lo-12 seconds in each in vivo microvoltammetric
represented

current was measured

oxidized with the amplitude of the oxidation

Logarithmic

within CA, region of hippocampus

data point,

are published by

between DA and NE, by in vivo

1988). In viva electrochemical

(pA) as a function of the semidifferentiation

NE and 5-HT in vitro, approached
(Broderick,

1990). The ability to distinguish

has been published (Broderick,

equates concentration

microelectrodes

1989). A review of the historical and technical aspects of the field of in vivo

to the concentration

electrochemical

.

of the three in vivo electrochemical

is cited (Broderick,

microvoltammetry

proportional

.

(Microvm:

The methods for the manufacture

in picoamperes

saline (body weight in cc/kg i.p.) immediately

a measurement

scan. NE release and S-HT release, at each

in pA of NE and S-HT current

within

CA,

Current for NE and 5-HT, was detected within the same synaptic environment.

region

of

Adinazolam.
In vivo microvoltammetric

(semidifferential)

rats were begun approximately
each experimental
23.5”).

diazepam. 5-HT. NE, open field behavior
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studies on freely moving and behaving Sprague Dawley

18 to 21 days after the aseptic surgical procedures

were performed.

day, an animal was placed in a faradaic, Plexiglas chamber (dimensions:

The three microelectrode

assembly,

enclosed

within the animal’s prosthetic

24”~ 18”~

acrylic cap, was

connected to a CV37 detector (BAS, West Lafayette, IN) by means of a mercury commutator
Instr., Princeton,

NJ), a flexible cable, and a mating connector

The CV37 was electrically

connected

to a Minigard

(BJM Electronics,

surge-suppressor

NY), which was then connected to an isolated electrical ground.

(Br. Res.

Staten Island, NY).

(Jefferson

Electric,

In vivo electrochemical

release and for 5-HT release within CA, region of hippocampus

On

Magnetek,

signals for NE

in the freely moving and behaving

animal were detected every five minutes; each five minute period included a two minute cell deposition
time.

Stable in vivo electrochemical

adinazolam

signals for NE release and 5-HT release were evident before either

(10 mg/kg i.p., first hour, 2 mg/kg ip., second hour) or diazepam (1 mg/kg i.p., first hour, 3

mg/kg i.p., second hour) was administered.

Adinazolam

(Pharmacia and Upjohn Co., Kalamazoo,

MI)

or diazepam (Sigma, St. Louis, MO) was dissolved in doubly distilled water; solutions were made fresh
on the day of each study.

The behavioral
adinazolam

chamber was novel to each animal, although each animal was habituated before either

or diazepam

double doors (dimensions
photobeams

was injected,

i.p.

The behavioral

chamber was equipped

15.75” x 23.5”) to enable a facile injection procedure.

was encased in aluminum frames around the chamber’s perimeter.

IBM computerized

circuit, the infrared photobeams

chamber on an x-y axes positional
were simultaneously
(running-forward

assayed.

locomotion

basis.

behavior

interacting

with the maintenance

of a horizontal

position

of the head

et al., 1990)), (2.) Rearing (maxima1 upward vertical movement

sniffing,

and grooming),

is called anti-agoraphobic

(combined

and (4.) Central Ambulations:

(anti-thigmotactic)

reduced fear on the part of the animal (Geyer, 1990)]. Mesolimbic
closely temporally

in the behavioral

Thus, multiple concurrent measures of the animal’s activity

activity in the central part of the chamber which indicates movements
Ambulatory

When activated with an

detected the animal’s position

the head, without lateral turning (Teitelbaum et al., 1990)). (3.) Fine Movements
of head bobbing,

A series of infrared

The specific activities of each animal assayed were: (1.) Ambulations

without lateral turning (Teitelbaum

movements

with side-by-side

of

stereotypic
[(locomotor

away from the walls.) (Central

behavior; the behavior

indicates a

5-HT release has been shown to be

allied with natural open-field movement (Broderick and Phelix, 1997). The status of

the infrared photobeams

was sampled every 100 msec. Our system is a modified version of an Activity

360
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Pattern Monitor (San Diego Instruments,
measures

of concurrent

San Diego, CA).

Data were computerized

and calculated as

and separate activities every five minutes, for each five minute time period,

during time course studies, for two hours.
ode Placw
Placement

of indicator

ferrocyanide

microelectrodes

in CA, hippocampus

was confirmed

in 10% formalin, blue dot method, with transcardial perfusion (80 ml saline).

electrical specifications
second time period.

Statistically

determined

for deposition

of the blue dot in CA, hippocampus

significant

differences
and behaving

Student-Newman-Keuls

animal, between
of Variance

Multiple Comparison

drug treatment

(ANOVA)

Neurochemical

statistically

differences

Methods for equal variances.

Kruskal-Wallis

or

One Way

Method, was used in the event of

Each component

of open-field

(2.) Rearing, (3.) Fine Movements

behavior [( 1.) Ambulations

and (4.) Central Ambulations],

was

Each animal was used as its own control.

Statistics revealed the most dramatic

between adinazolam and diazepam in the directional response occurred with the monoamine,

5-HT. Therefore,

5-HT results are presented first.

and 5-HT.

Figure 1 shows the effect of adinazolam

2 mg/kg i.p., second hour) on synaptic concentrations

hippocampus

(10 mg/kg i.p., first hour, and an
of 5-HT within the CA, region of

of the freely moving and behaving, male, Sprague Dawley rat. Adinazolam

the in vivo electrochemical

p<O.OOOl, H=19.9, d+2
statistically

the post hoc tests, Dunnet’s

analyzed, using the same statistical tests, described above. Behavioral results are expressed

as frequency of events.

increased

was

results are expressed as % of control to minimize animal variations.

Each animal was studied as its own control.
locomotion),

and same animal control,

applying

ANOVA on Ranks with post hoc test, Dunn’s Multiple Comparison

(running-fonvard

was 50 pA current in a 30

in NE release and 5-HT release within CA, region of hippocampus

by One Way Analysis

unequal variances.

The precise

Virtually no damage to brain tissue occurred.

in the freely moving

additional

by the potassium

significant

signal for 5-HT (Kruskal-Wallis

(N=4) (unequal variance)).

differences

One Way ANOVA

significantly
on Ranks:

Post hoc analysis further showed that there were

from baseline in the second hour of study (Dunn’s Method: pcO.05,

Adinazolam. diazepam. 5HT. NE. open field behavior
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q=4.06 (second hr.)).
Serotonin
maximally

release was increased to 115% over baseline (baseline=lOO%)
increased

to 209% above baseline

Further post hoc analysis,
hippocampus,
baseline

showed

(Dunnett’s

respectively)
F=46.4, d-,23

which delineated

within

one-half

90 minutes

after adinazolam

hour effects of adinazolam

that each of the four one-half

Method:

within 10 minutes and was

hour effects

(equal variance).

This post hoc analysis

(N--4) (equal variance).

followed

on 5-HT release in

was statistically

~~0.05; q=4.55, qE8.04, q=10.02, q=12.12: one-half

administration.

increased

over

hours 1 through 4

a One Way ANOVA:

p<O.OOOl,

Dramatic increases in 5-HT release occurred at the 30 min.

mark. Mean increases were 155.5% (first hour) and 197.5% (second hour).

240
220
200
160
160
140
120
100
60
60
40
20
0

-20
Pre-Drug

I

I

1

1

0

20

40

60

Adinazolem
(10 mglkg IP)

fX

I

I

60
100
Adinazolam
(2 mg/kg IP)

I

120

>
TIME IN MINUTES

Fig 1. Time course studies showing the effect of adinazolam on synaptic concentrations of 5-HT within
seconds of release,within CA, region of hippocampus in freely moving and behaving male, Sprague
Dawley rats. Each data point represents the mean +/- SE of endogenous synaptic concentrations of 5-HT
(N=4) followed by mean +/-SE of changes in synaptic concentrations of 5-HT produced by adinazolam
(N=4; same animal control).

P.A. Broderick et al.

362

Adlnazolam
additional

2 mg/kg

hippocampys
decreased

Figure 2 shows the effect of adinazolam
hour) on synaptic

the in vivo electrochemical

df=2 (N=4) (unequal

significant

(baseline=lOO%)

baseline.

of NE within

signal for NE (Kruskal-Wallis

difference

variance)).

CA1 region

One Way ANOVA

Post hoc analysis

showed

of

significantly
on Ranks:

that there was a

from baseline values in the second hour of the two hour time course

studies (Dunn’s Method: ~~0.05, q=3.492).

20 minute

concentrations

of the freely moving and behaving, male, Sprague Dawley rat. Adinazolam

p<O.OOOl, H=18.7,
statistically

i.p., second

(10 mg/kg i.p., first hour, and an

Initially, NE release was increased

114% over baseline

within 5 minutes, then remained increased for 15 minutes, returned to baseline at the

mark, was decreased

28% within

Within 90 minutes after adinazolam

below baseline was exhibited.

50 minutes

and eventually

administration,

decreased

to 41% below

a maximal 47% decrease in NE release

Due to the biphasic properties exhibited by adinazolam on hippocampal

NE ielease, the mean decrease

in the first hour was 8.2%, whereas the mean decrease in NE release

observed in the second hour of study was 36.3% below baseline values.
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Fig 2. Time course studies showing the effect of adinazolam on synaptic concentrations of NE within
seconds of release, within CA1 region of hippocampus in freely moving and behaving male, Sprague
Dawley rats. Each data point represents the mean +/- SE of endogenous synaptic concentrations of NE
(N=4) followed by mean +/-SE of changes in concentrations of NE produced by adinazolam (N=4; same
animal control).

Adinazolam.
and Frequency

of Ambulu

first hour, and an additional

with

Adinazolam
effect

was statistically

variance)).

(number)

(10 mgikg i.p.
of Ambulations

in each animal in which 5-HT release and NE release were detected

in vivo microvoltammetry.
increased
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Figure 3 shows the effect of adinazolam

2 mg/kg i.p., second hour) on the frequency

(running in forward locomotion)
on-line

diazepam. 5HT. NE, open field behavior

Adinazolam

exhibited

decreased

the frequency

and then subsequently
significant

(One Way ANOVA,

biphasic

behavioral

of Ambulations;

p<O.O046), F=5.05,

df-4,23

properties.
this biphasic
(N=4) (equal

Although adinazolam treated animals exhibited hyperactive behavior for 20 minutes, within
500 7

8
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Fig 3. Time course studies showing the effect of adinazolam on Ambulatory behavior in freely moving
and behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural
Ambulatory behavior (N=4) followed by mean +/-SE of changes in Ambulatory behavior produced by
adinazolam (N=4; same animal control). Behavioral chamber was novel to each animal; animals were
habituated before adinazolam injection.
30 minutes,

the animals displayed

When adinazolam

did not dramatically

studies, baseline conditions
points.

sporadically

reduced Ambulatory

reduce Ambulations

Movements

by more than 50%.

during the first hour of the time course

reappeared, actually followed by increases at the 40,45, and 55 minute time

After the second injection of adinazolam (2 mg/kg), although photobeam interruptions

increased

P.A. Broderlck et d
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from 3 I

to

104, statistical significance did not occur in this half-hour.

At the 90 minute mark, another

series of reductions occurred, eventually resulting in an increase of 10 photobeam interruptions at the
end of the time course study. Indeed, 50% of the animals exhibited dramatic increases in Ambulatory
activities at time points 15 and 115 and consequently

huger standard errors occurred.

Notably, initial

increases in Ambulatory activity are consistent with the increases in 5-HT release and the initial
increase in NE release. Post hoc analysis showed that adinazolam significantly increased the frequency
of Ambulations (Dunnett’s Method: ~~0.05, q=3.412) in the first half-hour after adinazolam injection.
The other three “q” values for the final three half-hours were not statistically significant over baseline;
q=O.168, q=O.585, qzO.134.
m

Figure 4 shows the effect of adinazolam (10 mgkg i.p., first

hour, and an additional 2 mg/kg i.p., second hour) on the fr equency of Rearings; each animal had
T
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Fig 4. Time course studies showing the effect of adinazolam on Rearing behavior in freely moving and
behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural Rearing
(N=4) followed by mean +/-SE of changes in Rearing behavior produced by adinazolam (N=4; same
animal control). Behavioral chamber was novel to each animal; animals were habituated before
adinazolam injection.

Adinazolam.
5-HT release
behavior

diazepam.

and NE release

monitored

was also concurrently

recorded.

5-HT. NE, open field behavior

on line, with in vivo microvoltammetry,
Adinazolam

did not significantly

(One Way ANOVA: ~~0.2605, F=l.42, df=4,23 (N=4) (equal variance)).
was increased

in the first half-hour post-injection

However,

similarly to the Ambulatory

were spurts of increased Rearing behavior demonstrated
Rearing events numbered
Adinazolam
adinazolam,
0.3978,

did not significantly
are individually

significant

affect Rearing frequency

However, Rearing frequency

decreased to mean values of 2, 4,

behavior exhibited

post-adinazolam,

there

throughout the 2 hour time course study, e.g.

12 at the 115 minute time point.
increase the Rearing frequency when the first and second hour, post-

compared to the baseline (Kruskal-Wallis

H = 1.84, df=2 (N=4) (unequal

statistically

and Ambulatory

when Rearing events increased from a mean baseline

value of 2 to a mean value of 8. Then, Rearing behavior dramatically
and 3 respectively.
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difference

variance)).

Further

One Way ANOVA on Ranks: p=

analysis

showed

that there was no

from baseline in the thirty minutes following each injection. (Kruskal-

Wallis One Way ANOVA on Ranks: pcO.236, H = 2.88, df=2 (N=4) (unequal variance)).
and F-v

of Fme Move-

(10 mgikg i.p., first hour, and an additional
Movements

2 mg/kg i.p., second hour) on the frequency

and in which Ambulations

significantly

Way ANOVA
movement

effect of adinazolam
of Fine

in each animal in which 5-HT release and NE release were detected on line, with in vivo

microvoltammetry,
Adinazolam

Figure 5 shows the concurrent

and Rearing frequency

increased the frequency of Fine Movements

were monitored

(Stereotypy)

concurrently.

(Kruskal-Wallis

on Ranks: p=<O.O03, H = 16.0, df=4, (N=4) (unequal variance)).

Stereotypic

One
fine

events increased from a mean of 1 (baseline) to a mean of 7, 6, 4 and 0 in the first half-hour,

second half-hour,

third half-hour,

and fourth half-hour of study respectively.

Q numbers derived from

the post hoc test (Dunn’s Method) showed that only the first half-hour effect was significant

(~~~0.05,

q=2.619).
Adinazolam’s

dramatic effects on increased stereotypy

five minutes post-injection
interruptions

period, as photobeam

to 18 photobeam

interruptions.

hour at the 2 mg/kg supplemental

doses.

(Fine Movements)

interruptions

were nine-fold

in the first

went from a baseline of 2 photobeam

Again, animals exhibited spurts of activity in the second

Sporadic increases were interspersed

with sedative profiles.
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Fig 5. Time course studies showing the effect of adinazolam on Fine Movement behavior (Stereotypic
Fine Movements of grooming and sniffing) in freely moving and behaving male, Sprague Dawley rats.
Each data point represents the mean +/- SE of natural Fine Movement behavior (N=4) followed by mean
+/-SE of changes in Fine Movement behavior produced by adinazolam (N=4; same animal control).
Behavioral chamber was novel to each animal; animals were habituated before adinazolam injection.

and Frewcv
adinazolam

Movement

(anti-agoraphobia)

Figure 6 shows

the concurrent

effect

of

in each animal in which 5-HT release and NE release were

on line, with in vivo microvoltammetry,
frequencies

One Way ANOVA

and in which Ambulations,

were monitored concurrently.

the frequency of Central Ambulations;

Adinazolam

Rearing,

increased and subsequently

this biphasic effect was statistically

significant

on Ranks, pcO.0197, H = 11.7, df=4 (N=4) (unequal variance)).

increase in the Central Ambulatory

behavior occurred in the first half-hour,

value was 2.0069 (p>O.O5). Adinazolam
injection,

m

(10 mg/kg i.p., first hour, and an additional 2 mg/kg i.p., second hour) on the frequency of

Central Ambulations
detected

of Central

at which time, the increased

began to exhibit anti-agoraphobia
response

was approximately

Photobeam interruptions,

and Fine
decreased

(Kruskal-Wallis
Although

an

the Dunn’s Method “q”
behavior ten minutes after

three-fold

higher than the mean

baseline for the Central Ambulatory

response.

which denote anti-agoraphobic

behavior, are increased Ambulations

(locomotor activity) into the center of the faradaic, behavioral

Adinazolam, diazepam. 5-HT. NE. open field behavior
chamber. The increased

injection

Central Ambulatory

Central Ambulatory

hour. Moreover,

the Central Ambulatory

second dose of adinazolam.
three-fold

response of adinazolam continued for thirty minutes post-

at which time, Central Ambulatory

second injection,

above baseline.

The transient
Ambulatory,

increases

367

movements

activity increased

decreased
five-fold

to zero.

Five minutes

over the last time point in the first

response diminished to zero at the twenty minute mark at the

Again, at the 115 minute mark, Central Ambulatory
Thus, adinazolam’s

and decreases

after the

anti-anxiety

effect can be discerned

in Central Ambulatory

behavior

behavior

increased

in this paradigm.

are similar to the pattern of

Rearing, and stereotypic Fine Movement behavior, seen in Figs 3,4, and 5.
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&_& Time course studies showing the effect of adinazolam on Central Ambulatory behavior in freely
moving and behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural
Central Ambulatory behavior(N=4)
followed by mean +/-SE of changes in Central Ambulatory
behavior produced by adinazolam (N=4; same animal control). Behavioral chamber was novel to each
animal; animals were habituated before adinazolam injection.
w

and 5-HT, Figure 7 shows the effect of diazepam (1 mg/kg i.p., first hour, and an additional

3 mg/kg i.p., second hour) on synaptic concentrations
freely moving and behaving,
electrochemical

of 5-HT within CA, region of hippocampus

male, Sprague Dawley rat. Diazepam significantly

of the

decreased the in vivo

signal for 5-HT (One Way ANOVA: p<O.OOOl, F=33.9, df=2,25 (N=5) (equal

P.A. Broderick et aL
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variance)).

Post hoc analysis showed that there was a statistically

significant

difference

from baseline

values in both the first and the second hours of the two hour time course study (Student-Newman-Keuls
Method: ~~0.05, q=9.92 (first hour), and q=ll.47
effect of diazepam on hippocampal

(second hour)).

The neurochemical

5-HT release was interesting; the effect was not dose-dependent;

maximum decrease was approximately

45% below baseline values (baseline=lOO%).

minutes after the second dose of diazepam (3 mg/kg i.p.) was administered.
note that diazepam
hippocampus

(at the 1 mg/kg dose) immediately

decreased

the

This occurred ten

However, it is important to

5-HT release within CA, region of

to 32.5% below baseline values. No significant difference occurred between the first hour

data (1 mgikg i.p.) and the second hour data (3 mg/kg) (Student-Newman-Keuls
q=2.19).

profile for the

The mean decrease

hour). A significant

Method:

p>O.O5,

in 5-HT release after diazepam was 29% (first hour) and 34% (second

return to baseline was not seen at the end of the 2 hour study.
160 ,
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Time course studies showing the effect of diazepam on synaptic concentrations of 5-HT within
seconds of release, within CA, region of hippocampus in freely moving and behaving male, Sprague
Dawley rats. Each data point represents the mean +/- SE of endogenous synaptic concentrations of 5-HT
(N=5) followed by mean +/-SE of changes in synaptic concentrations of 5-HT produced by diazepam
(N=5; same animal control).
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Figure 8 shows the effect of diazepam (1 mg/kg i.p., first hour, and an additional 3

mg/kg i.p., second hour) on synaptic concentrations

of NE within CA1 region of hippocampus

of the

Adinazolam.
freely moving and behaving,
electrochemical

diazepam.

5-HT. NE, open field behavior

male, Sprague Dawley rat. Diazepam significantly
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decreased

the in vivo

signal for NE (One Way ANOVA: p<O.O002, F=l 1.8,df=2,25 (N=S) (equal variance)).

Post hoc analysis further revealed that the significant effect of diazepam on NE release in CA, region of
hippocampus

occurred at both doses of diazepam studied, i.e. the 1 mg/kg dose and the 3 mg/kg dose

(Student-Newman-Keuls-Method:
diazepam on hippocampal

~~0.05, q=5.05 (first hour) and q=6.88 (second hour)).

NE release exhibited a similar profile to the colocalized

effect between

the first hour results (lmgkg)

seen (Student-Newman-Keuls-Method:

pr0.05;

5-HT release effects

A dose dependent effect did not occur; no

within the same synaptic terminal fields within hippocampus.
significant

The effect of

and the second hour results (3mg/kg) were

q=2.59). Immediately

diazepam decreased NE release within CA, region of hippocampus

within 5 minutes

of injection,

to 20% below baseline values; at the

25 minute mark, NE release began to show a return to baseline values but remained at about 5% below
baseline at the end of the first hour of study. Again, an immediate

decrease in NE release occurred,

____
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Fig 8. Time course studies showing the effect of diazepam on synaptic concentrations of NE within
seconds of release, within CA, region of hippocampus in freely moving and behaving male, Sprague
Dawley rats. Each data point represents the mean +/- SE of endogenous synaptic concentrations of NE
@J=5) followed by mean +/-SE of changes in synaptic concentrations of NE produced by diazepam
(N=5; same animal control).
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to approximately
significant,
baseline,

20% below baseline

after the second dose of diazepam; the second dose produced a

more lasting, yet modest effect on hippocampal
after the 3 mg/‘kg dose of diazepam,

NE release.

was observed.

A trend for NE to return to

The maximum decrease

in NE release

remained in the 20% below baseline range throughout the two hour time course of study.

The mean

decrease in NE release after diazepam was 10% in the first hour (first dose) and 15% in the second hour
(second dose).
am and Fremv

Figure 9 shows the effect of diazepam (lmglkg

i.p., first

hour, and an additional 3 mg/kg Lp., second hour) on the frequency (number) of Ambulations

(running

in forward locomotion)

of AX&&&XL

(locomotor

activity) in each animal in which 5-HT release and NE release were

detected, on-line and concurrently.

Diazepam significantly

decreased the frequency

of Ambulations

in

the 2 hour period of study (One Way ANOVA: ~~0.0032, F=7.31, df=2,25 (N=5) (equal variance)).
Post hoc analysis showed that there were statistically significant differences

Pre-Drug
<

z==z

Diazepam
(Imgkg IP)

_

from baseline in both hours

_

TIME IN MINUTES

Fig 9. Time course studies showing the effect of diazepam on Ambulatory behavior in freely moving
and behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural
Ambulatory behavior (N=5) followed by mean +/-SE of changes in Ambulatory behavior produced by
diazepam (N=5; same animal control). Behavioral chamber was novel to each animal; animals were
habituated before diazepam injection.

Adinazolam.

diazepam. 5-HT. NE. open field behavior
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(i.e. at both doses), during the two hour time course of study (Student-Newman-Keuls-Method:

q=4.919 (first hour) and q=5.176 (second hour)).

The effect of diazepam on Ambulations

similar profile

concentrations

hippocampus;
compared

to that of its effect on synaptic
there was no statistically

significant

difference

of 5-HT release

exhibited

and NE release

a
in

seen, when first hour dose effects were

with second hour second dose effects (Student-Newman-Keuls-Method:

Ambulations

~~0.05,

p>O.O5, q=O.363).

remained below baseline values throughout the two hour period of study.

Diazenam and Frequencv

of Rearinas, Figure 10 shows the effect of diazepam (lmgkg

i.p., first hour,

and an additional 3 mgikg i.p., second hour) on the frequency of Rearings in each animal in which 5-HT
release

and NE release

Ambulations
behavior
variance)).

were

detected,

on-line,

with

activity patterns were monitored concurrently.

(Kruskal-Wallis

One Way Anova

on Ranks:

in

viva

microvoltammetry,

Diazepam significantly
p<O.O053, H=lOS,

and in which
decreased

df=2 (N=5)

Rearing
(unequal

Post hoc analysis of the data further revealed a significant decrease in Rearing behavior after

diazepam occurred in both hours, i.e. at the Img/kg dose and at the 3 mgikg dose (Dunn’s Method:
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<

::

20

40

Diazepam
(lmglkg IP)

60
_

60

100
Diaze am
(3 mg Pkg IP)

120

TIME IN MINUTES

Fig 10. Time course studies showing the effect of diazepam on Rearing behavior in freely moving and
behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural Rearing
behavior (N=5) followed by mean +/-SE of changes in Rearing behavior produced by diazepam (N=5;
same animal control). Behavioral chamber was novel to each animal; animals were habituated before
diazepam injection.
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pcO.05, q=2.52 (first hour and q=3.24 (second hour)).

No statistically

significant

difference

occurred

between the two dose effects (Dunn’s Method: p>O.O5, q=l.Ol).

Therefore, the effects of diazepam on

Rearing behavior were not dose dependent

It is noteworthy

at the doses studied.

that the initial effect,

i.e. the first four time points after diazepam injection were similar to baseline values, but the standard
errors were correspondingly
m

high; the unusual response effect of one animal contributed to this effect.

and Frequency

of Fine Moveme&

first hour, and an additional
in each

animal

microvoltammetry,

Figure 11 shows the effect of diazepam (lmgikg

3 mgikg i.p., second hour) on the frequency (number) of Fine Movements

in which

5-HT

release

and NE

release

were

detected,

on-fine,

and in which ambulatory and rearing activity patterns were monitored

on-line, by infrared photobeams.

Diazepam significantly

decreased Fine Movement

50

u
p

in vivo

concurrently,

Post hoc

1

/

i:

9

with

behavior (Kruskal-

Wallis One Way ANOVA on Ranks: p<O.O095, H=9.30, df=2 (N=5) (unequal variance)).
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Fig 11. Time course studies showing the effect of diazepam on Fine Movement behavior (Stereotypic
Fine Movements of grooming and sniffing) in freely moving and behaving male, Sprague Dawley rats.
Each data point represents the mean +/- SE of natural Fine Movement behavior (N=5) followed by mean
+/-SE of changes in Fine Movement behavior produced by diazepam (N=5; same animal control).
Behavioral chamber was novel to each animal; animals were habituated before diazepam injection.

Adinazolam.

analysis revealed

that the statistically

(Dunn’s Method: ~~0.05, q=2.90).

diazepam. 5-IIT, NE. open field behavior

significant
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decrease occurred at the 3 mgikg dose of diazepam

There was no statistically

significant

difference

in effects between

the first hour dose (1 mg/kg) and the second dose (3 mgikg) (D unn’s Method: ~~0.05, q=1.90).
initial Fine Movement
response

to diazepam

response

at the 1 mgikg dose. occurred

to diazepam,

at the 1 mgikg dose of diazepam.

animal which contributed

The

similarly to the Rearing

It was again, the unusual response

of one

to this behavioral effect; it was, in fact, the same animal who had provided the

unusual Rearing response.
Figure 12 shows the effect of diazepam (lmgikg
i.p., first hour, and an additional
Ambulations

(anti-agoraphobia,

3 mgikg i.p., second hour) on the frequency

anti-thigmotactic

!
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Pre-Drug
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of Central

behavior) in each animal in which hippocampal

release and NE release were detected, on-line, with in viva microvoltammetry,
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and in the same animals
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Fig 12.
moving
Central
behavior
animal;

Time course studies showing the effect of diazepam on Central Ambulatory behavior in freely
and behaving male, Sprague Dawley rats. Each data point represents the mean +/- SE of natural
Ambulatory behavior (N=5) followed by mean +/-SE of changes in Central Ambulatory
produced by diazepam (N=5; same animal control). Behavioral chamber was novel to each
animals were habituated before diazepam injection.
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in which Ambulatory,
line, by infrared

Rearing, and Fine Movement

photobeam

(little or no entries

detection.

Diazepam

of diazepam

on Fine Movement

q=2.481). Since increased
reduction response
diazepam

Ambulations

a marked

enhanced

(Kruskal-Wallis

concurrently,

the agoraphobic

One Way ANOVA

(3mg/kg

effects)

(Dunn’s

behavior
on Ranks:

Method:

in the center of the chamber has been associated

sedation

~~0.05,

with a fear

effect] of a drug (Geyer, 1990), it is noteworthy

which

on-

The post hoc analysis showed a similar profile to

behavior,

[anxiety reducing (anxiolytic)

produced

Ambulatory

significantly

into the center of the chamber)

~~0.0344, H=6.74, df=2 (N=5) (unequal variance)).
the effect

activity patterns were monitored

masked

its anxiolytic

properties

in this

that

Central

paradigm.

Discussion

Anxiety and Depression
Always pertinacious
treat depression

has been the role for 5-HT in the mechanism

(Coppen et al., 1963; Walinder et al., 1976; Menkes et al., 1980; Wang and Aghajanian,

1980; van Praag, 1981; Broderick
Asberg et al., 1985; Goodwin,
et al., 1989; Broderick
1993; Dubovsky,

and Lynch, 1982; Chamey et al., 1984; de Montigny

and Piercey,

1994; Preskom

1990, 1991; Broderick,

two to three weeks to provide

adequate pharmacotherapy

critical

1996; Broderick,

(Pyke et al., 1983). Therefore,
a tactical

improving antidepressant
Serotonin. Adinazolam

deciphering

manipulation

for depression.

Importantly,

the TBZD,

within two to seven days post initiation

the mechanism

of the synapse,

of action for the TBZDs is

in order to determine

strategies

for

and Diazem
action of the TBZD, adinazolam

The present results show that the mechanism

different

Kline (1974)

therapy.

This paper is the first report of an immediate
(single) injection.

1997).

after 5-HT drugs such as the TCAs, could take as long as

has been shown to produce a marked improvement

for assessing

dramatically

199la; Post et al., 1992; Mongeau et al.,

et al., 1994; Baldessarini,

improvement

of treatment

et al., 1984;

1986; Price et al., 1986; Blier et al., 1987; Broderick et al., 1989; Mann

though, showed that measurable

adinazolam,

of action of drugs classically used to

of action of the TBZD, adinazolam

from that of the classical BZD, diazepam.

within the CA, region of hippocampus
was not at all like the response
CA, region of hippocampus

on 5-HT after acute

Adinazolam

increased

while the animal is freely moving and behaving.

of the classical BZD, diazepam, which decreased

using the same freely moving paradigm.

is

5-HT release
This response

5-HT release within

The present data support previous

Adinazolam,
preclinical

diazepam. 5-HT. NE, open field behavior

data which indicate that (a) the TBZD, adinazolam,

(Tunnel and de Montigny,
was increased

1984) (b) the BZD, diazepam,

by movement

TBZD, alprazolam
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acts through the monoamine,

decreased hippocampal

5-HT

5-HT release, which

in the X-Maze in the freely moving rat (Wright et al., 1992) and (c) the

also increased CA, hippocampal

5-HT release (Broderick,

1997). Furthermore,

our

results are consistent

with the previous studies of Turmel and de Montigny (1984) in the sense that the

TBZD, adinazolam,

had different effects on 5-HT-ergic

Tunnel and de Montigny studies,

diazepam did not induce 5-HT sensitization

the same 5-HT somatodendrites
The present
inhibited

behavior

with another previous

(Kostowski

et al., 1986).

increase in central 5-HT levels, has been previously
1982). Moreover,

our hypothesis

in neuronal tiring.

study which reported

Diminished

reported

aggressive

that adinazolam

behavior

through an

(Malick, 1978; Broderick

that a more sensitive technique

In the

in neuronal firing within

in which adinazolam did induce 5-HT sensitization

results are also consistent

aggressive

function than did the BZD, diazepam.

and Lynch,

such as in vivo microvoltammetry

would better reveal 5-HT effects of adinazolam with better temporal and spatial resolution, is supported.

An overview
activity

of the scientific

from the BZDs,

antidepressant

activity

literature reveals that the TBZDs differ strikingly in pharmacological

in that the TBZDs

show positive

results

(Sethy and Hodges,

preclinical

of NE-induced

1982). The present data may lend explanation

data in the literature,

about adinazolam,

which directly

conflict

clinical literature. To reiterate, the previous data reported that adinazolam
reuptake at the synapse,
cortex beta adrenergic

in vitro, and adinazolam,
receptor

binding

appears that a notable difference

when chronically

(Sethy and Harris,

pyramidal neurons to microiontophoretically

induced decrease
Using

the in vivo electrochemical

in the freely moving
was

and behaving

neither reduced rat
rat hippocampal
1984). Moreover, it

of action of the TBZD, adinazolam,

Whereas adinazolam

initially increased NE

in the freely moving and behaving

signal for NE.

revealed.

with highly

rat, a magnitude

adinazolam

and diazepam

hippocampal

NE release whereas diazepam produced a monophasic

Adinazolam

discrepant

was a weak inhibitor of NE

Moreover,

the adinazolam-

in NE release was greater than the decrease in NE release produced
biotechnology,

of blood

with the data from the

1981), nor sensitized

occurs between the mechanism

the in vivo microvoltammetric

resolution

to previous

administered,

release and then decreased NE release in CA, region of hippocampus
only decreased

enhancement

applied NE (Tunnel and de Montigny,

versus that of the BZD, diazepam where NE is concerned.

rat, diazepam

used to test

(Hester et al., 1980; Lahti et al., 1983; Sethy et al., 1984). The present results

agree with these positive results, e.g., the report of potentiation
pressure

in some assays

sensitive

difference

produced

temporal

and spatial

in NE effects

a biphasic

response.

by diazepam.

response

between
on CA,
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The present results confirm

the hypothesis

adinazolam on the monoamines,

that anesthesia

could have been masking

NE and 5-HT, as reported in the previous literature.

the effects of

Anesthetic

effects

of the TBZDs on 5-HT release are especially intriguing because in a similar series of studies from this
laboratory, adinazolam
chloral

hydrate

adinazolam
anesthesia

did not produce increased 5-HT release in the CA, region of hippocampus

anesthetized

animal

after acute (single)

injection

(Broderick,

1991a).

in the

Although

has been shown to be well tolerated in patients who must undergo surgery under general
(Othmer

and Othmer,

1988), the direct on-line effects

function and release, during adinazolam
effect to modify

deserves consideration.

dorsal raphe 5-HT neuronal firing after acute injection

1984), might be dependent,

on neurotransmitter

The lack of adinazolam’s
(Tunnel

and de Montigny,

in part, on anesthesia, since Aghajanian showed in 1978 that administration

of 5-HT in nerve terminals,
spontaneous

treatment,

of anesthesia

should suppress DR neuronal tiring.

Moreover,

firing rate of the DR, even though both systemic and iontophoretic

BZDs did not alter the
administration

were found to potentiate the inhibitory effects produced by GABA on DR (Gallagher,
firing rates have previously
catecholamines

been shown to be affected

(Kelland et al., 1989).

Therefore,

by anesthesia,

anesthestic

of BZDs

1978). Nerve cell

particularly

in the case of

effects may well alter nerve cell firing

rates, apriori, thereby masking the effects of adinazolam on 5-HT.
This laboratory

has studied the potency

release (Broderick,
butyrolactone,

to affect endogenous

1991b), using the neuronal impulse inhibitor and depolarization

(GBL), (Walters and Roth, 1972, 1974).

is also an anesthetic,
decreasing

of chloral hydrate anesthesia

5-HT

blocker, gamma-

In the presence of chloral hydrate, GBL, which

(Winters and Spooner, 1965), neuronal 5-HT depolarization

S-HT release which is dependent on impulse flow.

was blocked, thereby,

On the other hand, in the freely moving

and behaving rat paradigm, when neuronal impulse flow was blocked by GBL, but chloral hydrate was
not present,
inhibitory

5-HT release was not blocked (Broderick,
5-HT autoreceptor

mechanisms,

1992); these data suggest that GBL blocks

which results in enhanced

indicate that chloral hydrate may act to maintain inhibitory presynaptic
neuronal impulses subsequently
adinazolam’s
depend

These results

autoreceptors

and that 5-HT

Taken together, the data suggests that

effects on 5-HT release in the chloral hydrate versus the freely moving rat paradigm, may

on presynaptic

mechanisms

differ when anesthesia is present.

S-HT release.

5-HT autoreceptors.

for antidepressant

Thus, we agree with Blier et al., (1987)

action reside in presynaptic

5-HT autoreceptors.

that critical

Adinazolam.
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. .
Behavior.
The Behavioral

Activity Patterns gleaned from adinazolam

that adinazolam
observed

inhibited,

vs. diazepam administration,

at least in part, the normal agoraphobia

after an animal is placed in a novel environment

known anti-anxiety
diazepam,

even

administration.

doses,

is clearly

showed that the TBZD, adinazolam,
parameters,

more

potent

than

1990).

In contrast,

The sedative
that

observed

diazepam’s

effect produced
during

by

adinazolam

significant

signals for NE release and 5-HT release were detected on-line,
produced

at least in certain

decrease the frequency
exhibited

(Geyer,

The Behavioral Activity Patterns, which were derived from the same animals and at the

same time as the in vivo electrochemical

behavioral

(anxiety) behavior, which is usually

effect was masked by its sedative properties.
at low

demonstrate

a significant

specific

on Rearing Behavior,

time periods.

for example.

spurts of increased open-field

reduction

in three of the four open-field

Adinazolam

did not significantly

However, the adinazolam

behavioral

treated animals

activity distinct from the uninterrupted

sedative behavior which was produced by diazepam.
That adinazolam

produced

some sedative

properties

in the clinical

situation

has been reported

(O’Connor et al., 1985; Amsterdam

et al., 1986; Feighner,

properties

have been delineated by clinical studies as “limited” (Kramer and

Schoen,

produced

by adinazolam

1986; Cohn et al., 1988). However, sedative

1986) and as “rare” (Pyke et al., 1983). Our data are also consistent

which have shown that the TBZDs have less sedative properties

with preclinical

than the classical

studies

BZDs (File and

Pellow, 1985). It is widely known that the BZDs exhibit sedation, but, since adinazolam has little or no
anticholinergic

affects (Feighner,

1986), it is not surprising that adinazolam produced a lesser sedative

effect than did diazepam in the freely moving and behaving rat animal model.

.
)BZD 1s_,

Not to be ignored in the quest to reveal the mechanism
comparison

between

a TBZD,

lorazepam or clonazepam.
of comparing
results

lorazepam

Controlled

the antidepressant

have shown

that similar

or alprazolam

such as adinazolam,

and a high affinity

GABA-A-TBZD,

clinical studies have been performed with the expressed

effects of TBZDs with those of high affinity GABA-A-BZDs
antidepressant

vis-a-vis clonazepam

al., 1995, Romach et al., 1995, Davidson,
these controlled

of action of the TBZDs is a discussion

efficacy

is produced

by e.g. alprazolam

of the
such as
purpose
and the

vis-a vis

(Burrows et al., 1993, Pollack et al., 1993, Laakman et

1997). Although adinazolam per se, has not been included in

studies, it is likely that one could extrapolate a similar result for adinazolam as well.

But, that TBZDs have similar efficacy to lorazepam and clonazepam
question: do both TBZDs and high affinity GABA-A-BZDs

in clinical depression,

begs the

act through the exact same mechanism

on

P.A. Broderick et al
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5-HT? The literature, for the most part, argues against this hypothesis
e.g. one study showed
syndrome,

and diazepam

whereas the 5-HT reuptake inhibitor,

helplessness

syndrome

presumably
combined

that both lorazepam

either

(Martin

a direct effect

interactive

NE/S-HT

anxiolytic/antidepressant
Nevertheless,

et al., 1996).

1996),

were unable to reverse the helplessness

fluvoxamine,

produced

a significant

reversal of the

Thus, further evidence

is presented

here that it is

of adinazolam
effects

(Gardner, 1986; Jefferson,

to increase

of adinazolam

hippocampal

5-HT release,

that may account

or some

for its unique

clinical

activity.

there are considerations

of other possible

interactions

of the triazolos

for producing

gradations of antidepressant,

as well as anxiolytic activity. Some of these mechanisms

hetero-oligomeric

subunit control of GABA gated CL- channels (Mihic et al., 1994, Costa

and Guidotti,

GABA-A

1996), wherein potentiation

factor (PAF) antagonism

wherein

production in macrophages
mechanisms,

of GABA-A responses

blockade

could occur,

of calcium mobilization

could be e.g., (a)

(b) platelet activating

could reduce superoxide

(Gardner et al., 1993; Travers et al., 1995) and/or (c) cytochrome

which could increase triazolo levels for enhanced activity (Nemeroff

remain as exciting adjunct and/or alternative mechanisms

for exploration

anion

P450-3A4

et al.,1996).

into the mechanism

These

of action

of the TBZDs.

.
5-HTME Interactions.
A final note points to the interaction
antidepressant/anxiolytic

effects of adinazolam. The recent development

mixed 5-HT/NE transport antagonist
even potentiation

type,

therapeutic

including

antidepressant
adinazolam,

provide

of the compound venlafaxine,

alprazolam,

a strong

adinazolam,

and zometapine,

and anti-anxiety

that the separation of the in vivo hippocampal
empirical

explanation

interactions,

Specifically,

synaptic mechanism

the hypothesis

truly

of action

of the dual

action from that

Moreover,

of a mixed aminergic action, i.e. an interactive
effects, is likely.

a

in the case of the TBZD,

increased 5-HT-ergic effects on release.

for its dual antidepressanttanxiolytic

represent

1996).

the data indicates that the modus operandi which separates adinazolam’s

of the TBZD, adinazolam,

perhaps

5-HT release effects of

for the mechanism

action produced by the TBZDs.

of the BZD, diazepam, is adinazolam’s

a

(Leonard, 1994). Drugs of the TBZD type

approach to mixed anxiety and depression (Baldessarini,

The data support our hypothesis
the TBZDs

of action for the dual

speaks to the principle of mixing aminergic

in the treatment of anxiety and depression

and the “pyradolo”
“borderland”

of 5-HT and NE as the mechanism

in the case

5-HT and NE

Adinazolam,

diazepam.

5-HT. NE,open field behavior
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